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A b s t r A c t
bAcKGrOUND: Drug eluting stents (DES) have ushered in a new era in percutaneous 
coronary intervention (PCI), curtailing significantly the restenosis rates compared 
with bare metal stents (BMS). However, their use has been plagued with the late stent 
thrombosis phenomenon.
ObJEctIVE: During a 5-year period, sirolimus-eluting stents (SES) were employed in 
260 patients among 675 consecutive patients submitted to PCI by a single-operator 
with a uniform technique. The objective of this study was to assess the clinical and 
angiographic results and to report the incidence of stent thrombosis and the long-term 
outcome in these patients.
MEtHODs & PAtIENts: A consistent single-operator approach with 0.5 mm stent 
oversizing and high pressure (>12-18 bar) stent deployment was adopted, routinely 
combined with long-term dual antiplatelet therapy for at least a two-year period post-
implantation. The study included 213 men and 47 women, aged 64±12 years, who 
presented with stable angina and/or positive exercise test (n=54), unstable coronary 
syndrome (n=125), or acute myocardial infarction (MI) (n=81). The dilated vessel 
was the left main stem (n=4), left anterior descending and/or its diagonal branch 
(n=178), the right coronary (n=103), the circumflex and/or its obtuse marginal branch 
(n=89), the ramus branch (n=10), a saphenous vein (n=11) or arterial (n=2) graft. 
Three groups were compared: 104 (40%) patients receiving SES alone (Group A), 122 
patients receiving SES plus other DES (Group B), and 34 patients receiving SES plus 
BMS (Group C).
rEsULts: The majority (93.8%) of PCI procedures were performed adhoc during the 
same session of coronary angiography. All 3 groups had similar demographics, mean 
age (62-66 years), initial stenosis (88-89%) and mean ejection fraction (45-55%). Pro-
cedural success (99-100%) and residual stenosis (<0-10%) were also similar. Multives-
sel PCI and stenting was performed in 120 (46.3%) patients and multilesion PCI in the 
majority (89.2%) in this cohort. Overall, a mean number of 1.6±0.7 vessels and 3.1±1.6 
(range, 1-9) lesions were dilated. A median of 2 stents (mean of 2.6±1.3 stents) were
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I N t r O D U c t I O N
Percutaneous coronary intervention (PCI) has been mark-
edly facilitated by the use of drug eluting coronary stents (DES) 
which have a most favorable outcome with a significantly lower 
restenosis rate compared with bare metal stents (BMS) ac-
cording to data from both randomized studies and registries.1-3 
However, over the recent several years we have poignantly be-
come aware of a potentially serious problem, that of late stent 
thrombosis which has led to repeated major guideline revisions 
regarding the duration of dual antiplatelet therapy.3-9 Over 
a 5-year period, a uniform approach with approximately 0.5 
mm stent oversizing and high-pressure (>12-18 bar) deploy-
ment10-12 was adopted by a single operator, routinely combined 
with long-term dual antiplatelet therapy and the clinical and 
angiographic results are presented in a prospective series of 
260 consecutive patients receiving sirolimus eluting stents 
(SES) alone or SES combined with other DES and/or BMS. 
P A t I E N t s  A N D  M E t H O D s 
PA t I E N t s
Over the last 5 years, among 675 consecutive patients 
who were submitted to PCI by a single operator, 260 patients 
received SES alone or SES combined with other DES and/or 
BMS. The study included 213 men and 47 women, aged 64±12 
years (range, 35-88) who presented with stable angina and/
or positive exercise testing (n=54), acute coronary syndrome 
(n=125), or acute myocardial infarction (MI) (n=81) (Table 
1). A history of previous MI (dated from 1 week to several 
years) was present in 32 patients, of previous PCI in 25 patients 
and a history of prior “bypass” surgery in 20 patients. Dilated 
vessels included the left main (LM) (n=4), the left anterior 
descending (LAD) and/or its diagonal branch (n=178), right 
coronary artery (RCA) (n=103), left circumflex (LCx) and/or 
its obtuse marginal branch (n=89), ramus intermedius (n=10), 
and venous (n=11) or arterial (n=2) grafts. Three groups were 
compared: 104 patients receiving a SES, 122 patients receiv-
ing a SES plus another DES and 34 patients who received a 
SES plus a BMS. Procedures were performed at an institution 
with cardiovascular surgery back-up. Possible complications 
and risks, as well the benefits of each procedure, and the 
availability of surgical “bypass” as an alternative method of 
revascularization were all made explicit to the patient and the 
patient’s family, and informed written consent was obtained 
from the patient before the procedure.
As the majority (79%) of patients in this series had acute 
coronary syndromes admitted via the emergency room or 
transferred from other institutions, they routinely received 
loading doses of antiplatelet drugs (aspirin and clopidogrel) 
at least upon arrival in the emergency room. Also routinely 
upon admission all patients received a statin regardless of the 
cholesterol status. The primary end-point of the study was to 
assess the clinical and angiographic results and to report the 
incidence of stent thrombosis and the long-term outcome of 
these patients.
c O r O N A r y  A N G I O G r A P H I c  A N A Ly s I s
Lesions were classified according to the American College 
of Cardiology-American Heart Association classification13 and 
its subsequent modification.14 Reference vessel and lesion 
diameters were measured with use of manual (n=206) or 
automated (n=54) calipers at selected frames at end-diastole 
in views showing the worst degree of stenosis without overlap 
and with the least foreshortening. The guide catheter filled 
with contrast was used as reference.
P c I  P r O c E D U r E
All patients having an adhoc PCI procedure (n=244) re-
ceived a bolus of 2500 units of heparin after vascular access was 
obtained usually from the right femoral artery. After comple-
tion of coronary angiography and before proceeding with PCI, 
additional heparin (5000 units) was administered. For elective 
PCI (n=16), an initial bolus dose of 7000 units of heparin was 
employed. For procedures lasting longer than 1 hour if the ac-
tivated clotting time (ACT) could not be monitored additional 
implanted in 260 patients; group A (patients receiving SES alone) received the least number of stents (1.7±0.7). There was one 
occurrence of subacute stent thrombosis in group C (0.4%). All patients received combined therapy with aspirin and clopidogrel, 
the latter administered for >24 months. Over 16.3±14.7 months of follow-up, survival free of events (death, MI, stroke, repeat 
revascularization and restenosis) was excellent at 98%, 96%, and 97% at 12 months and 95%, 90% and 97% at 24 months for 
groups A, B and C respectively; long-rank (Mantel-Cox) test p value= 0.27. Clinical restenosis rates were low in all 3 groups (0% 
vs 1.6% vs 5.9%) (p=NS). Possible very late stent thrombosis could be suspected in 1 patient (group B) who had sudden cardiac 
death at 32 months after the procedure.
cONcLUsION: In a consecutive series of 260 patients receiving SES and/or other stents, a uniform single-operator approach with 
0.5 mm stent oversizing and high-pressure (>12-18 bar) deployment routinely combined with long-term dual antiplatelet therapy 
resulted in high procedural success (>99%), very low rate of subacute (0.4%) and late stent thrombosis (0.4%), very low clinical 
restenosis rates (0-5.9%) and overall excellent survival free of cardiovascular events at 1 and 2 years.
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tAbLE 1. Clinical and Anatomical Characteristics of 260 
Consecutive Patients Receiving SES
Men/Women 213/47
Age (years) 64±11.7
Clinical presentation
Stable angina/positive ETT 54
Unstable angina 125
AMI 81
STEMI 42
NSTEMI 39
Previous MI 32
Previous PCI 25
Previous CABG 20
Vessel(s)
LM 4
LAD/D 178
LCx/OM 89
RCA 103
RI 10
SVG 11
LIMA/Rad 2
CTO 10
Number of vessels stented 1.6±0.7
One 140
Two 87
Three 33
Number of lesions 3.1±1.6
LVEF 50±11%
Initial stenosis 88±7%
AMI= acute myocardial infarction; CABG= coronary artery bypass 
grafting; CTO= chronic total occlusion; D= diagonal; ETT= exercise 
tolerance test; LAD= left anterior descending artery; LCx= left 
circumflex coronary artery; LIMA= left internal mammary; LM= 
left main; LVEF= left ventricular ejection fraction; MI=myocardial 
infarction; OM= obtuse marginal; PCI= percutaneous coronary 
intervention; Rad= radial (artery); RCA= right coronary artery; RI= 
ramus intermedians; SES= sirolimus eluting stents; SVG= saphenous 
vein graft
2000-3000 units of heparin was given, or if ACT was measured, 
heparin was given in doses needed to maintain the ACT >300 
sec throughout the procedure. Mostly 6Fr or occasionally 7Fr 
sheaths and guiding catheters were used. A variety of rapid 
exchange balloon catheters were employed. Nonionic contrast 
agents were mainly used. Routinely 200 μg of intracoronary 
nitroglycerin was used initially before dilation, and repeated 
after each dilation to achieve maximal coronary vasodilation 
prior to final angiographic assessment estimated visually. 
s t E N t  I M P L A N t A t I O N
Coronary stents were implanted electively but also for 
coronary artery dissection of any degree observed visually. 
Monorail (rapid exchange) coronary angioplasty systems 
were utilized for all stent implants. Stent implantation was 
considered successful if residual stenosis was visually <10-
20%, there was no discernible dissection or thrombus and 
the resultant flow was TIMI grade 3. Stent sizes ranged from 
8 mm to 33 mm in length and 2.25 mm to 4.0 mm in diam-
eter. In addition to the Cypher™ stent (Johnson & Johnson, 
Cordis Unit, Miami Lakes, Florida), the predominant types of 
stents used in these patients were the Endeavor™ (Medtronic 
Inc., Minneapolis, MN, USA), Xience™ (Abbott Vascular, 
Santa Clara, CA, USA), NirFlex™ (Medinol Ltd, Tel-Aviv, 
Israel), Genous™ (OrbusNeich Medical Technologies, Fort 
Lauderdale, FL, USA), and MGuard™ (InspireMD Ltd., Tel 
Aviv, Israel) stents. Lesions had been either predilated with 
undersized standard angioplasty balloons or direct stenting 
was performed, when deemed feasible, with no prior balloon 
dilation. 
Routinely high-pressure inflation (>12-18 bar) and over-
sized (by approximately 0.5 mm) stents were employed.10-12 
As stents were mounted on high-pressure balloons and thus 
for stent deployment additional balloons for postdeployment 
inflation were not generally needed in the majority of patients. 
Stent deployment was assessed angiographically by visual 
estimation. Intracoronary ultrasound was not used. Vessels 
with reference diameter >2.25-2.5 mm were considered for 
stenting. Thromboaspiration was employed as needed with 
use of aspiration catheters for extraction of intraluminal 
thrombi. Bifurcation lesions were approached with a policy 
of provisional stenting with use of modified T-stenting and 
mini-crush techniques, depending on the presence or absence 
of ostial disease in the side-branch.15
For pre-planned procedures an attempt was made to use 
pretreatment with a 3-day regimen of aspirin (325 mg daily) 
and clopidogrel (75 mg daily); for patients not having been on 
aspirin or clopidogrel before the procedure, a dose of 300-500 
mg of aspirin and a dose of 300 mg or occasionally 600 mg of 
clopidogrel was given the day of the procedure. For patients 
with angiographically demonstrated intracoronary thrombi, a 
platelet glycoprotein IIb/IIIa inhibitor (tirofiban or eptifiba-
tide) was infused intravenously at an initial bolus dose and then 
continued at standard infusion rates for 24 hours. Administra-
tion of a IIb/IIIa agent was also considered for patients with 
balloon-induced coronary dissection, implantation of multiple 
stents, or angiographically high-risk coronary lesions, particu-
larly in diabetic patients or patients with elevated troponin. 
Tirofiban was administered as an initial loading dose of 0.4 
μg/kg/min and then decreased to infusion maintenance dose 
of 0.1 μg/kg/min at 30 minutes later. Eptifibatide was given 
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as an initial single bolus of 180 μg/kg, and the infusion at 2.0 
μg/kg/min (or 1.0 μg/kg/min if the creatinine was elevated) 
was commenced concurrently with the first bolus. In cases of 
bleeding, the dose was decreased or the infusion discontinued. 
Vascular sheaths were removed immediately after the end 
of the procedure and hemostasis was obtained with use of a 
hemostatic closure device (Angio-Seal™; St. Jude Medical, 
Inc, St. Paul, MN, USA) for all patients. 
Procedural success for all procedures was defined as a re-
sidual stenosis <20% without a major cardiac event, including 
death, Q-wave myocardial infarction or need for emergency 
coronary artery bypass during hospital admission. Myocardial 
infarction was defined according with the universal definition 
of myocardial infarction criteria.16 
P O s t P r O c E D U r A L  M A N A G E M E N t  A N D 
f O L L O w - U P
All patients received aspirin 325 mg once daily indefinitely, 
and clopidogrel 75 mg once daily for at least 2 years. Patients 
were followed up at the outpatient clinic or by their referring 
cardiologists. They routinely underwent exercise testing ini-
tially at 4 to 6 weeks and then at 3 and 6 months and annually 
thereafter. In diabetic patients, those unable to exercise or 
those with multivessel PCI, thallium scintigraphy was advised 
at 3-6 months and annually thereafter. Angiographic follow-
up was not routinely obtained, but coronary angiography was 
performed only for clinical recurrence of angina or positive 
exercise testing or radionuclide scintigraphy. Restenosis was 
defined as clinical recurrence and/or objective evidence of 
ischemia by exercise testing or thallium scintigraphy and a 
diameter stenosis >50% at repeat angiography.
The consensus criteria of the Academic Research Consor-
tium were adopted as general guidance for the definitions of 
clinical end points and stent thrombosis.17 Particularly, overall 
cardiovascular outcome during long-term follow-up related to 
all cardiovascular events including death, MI, stroke, repeat 
revascularization and restenosis. 
s t A t I s t I c A L  A N A Ly s I s
Continuous variables are expressed as mean±SD and cat-
egorical variables as a percentage and/or as a numerical value. 
Differences between data in the three groups were determined 
by analysis of variance with Bonferroni posthoc correction for 
quantitative data and by the chi-square test and the z statistic 
for qualitative data; life table analysis was performed with use 
of the Kaplan Meier method and comparisons were made with 
the long rank test, all with use of the Statview 5.0.1 program 
(SAS Institute Inc., Cary, NS, USA). A statistically significant 
difference was accepted at a level of p<0.05. 
r E s U L t s
P r O c E D U r A L  c H A r A c t E r I s t I c s
Clinical and angiographic characteristics of the study popu-
lation are described in Tables 1 and 2. The majority (93.8%) 
of PCI procedures were performed adhoc during the same 
session of coronary angiography. Stenting was successful for 
all vessels attempted in 257 (98.8%) patients. Direct stenting 
(no balloon pre-dilation) was feasible for at least one vessel 
in 25 (9.6%) patients. Revascularization failed in one vessel 
(RCA) of each of two patients undergoing two- or three-vessel 
PCI due to inability to cross the lesion with the wire (n=1) or 
dilate the vessel with the balloon (n=1); in another patient 
attempted two-vessel PCI failed in one vessel (LCx) due to 
inability to cross the lesion with the wire, while a Cypher stent 
could not be advanced in the other vessel (diagonal branch) 
and another smaller DES (Endeavor Resolute) was success-
fully deployed instead. 
Three groups were compared: 104 patients receiving SES 
alone (Group A), 122 patients who also received other DES 
(Group B) and 34 patients who received a SES plus BMS 
(Group C) (Table 2). The three groups had similar demograph-
ics, age, risk factors, initial vessel stenosis and left ventricular 
ejection fraction (Table 2). Lesion characteristics were differ-
ent, as well number of stented vessels and lesions; with group 
A having the smaller number of vessels and lesions stented 
and thus receiving the least number of stents. The following 
stents were employed: Cypher alone (patients, n=104), Cypher 
plus Endeavor (n=118), and/or Xience (n=7), Nobori (n=1), 
Intrepide (n=1), NirFlex (n=9), Costar (n=5), MiniVision 
(n=1), Genous (n=55), MGuard (n=7), and Jostent (graft 
stent) (n=3) (Table 3). A median of 2 stents (mean of 2.6±1.3 
stents; range, 1-8) were implanted in 260 patients. Single 
stents were used in 43 patients, 2 stents in 95 patients, and 
>3 stents in the remainder. There was one event of subacute 
stent thrombosis at 4 days after the initial procedure (Fig. 1). 
This was a patient who presented with inferolateral NSTEMI 
and coronary angiography revealed subtotal occlusion of both 
the RCA and an ectopic LCx originating from the proximal 
RCA; the LCx had long diffuse curved stenoses requiring the 
implantation of 3 cypher stents; a grafted stent was placed in 
the RCA due to local ectasia/aneurysm. Despite the adminis-
tration of standard antithrombotic therapy and the addition of 
a IIb/IIIa agent (tirofiban), 4 days post-procedurally the patient 
developed acute symptomatology and ECG signs of an acute 
inferolateral STEMI. Repeat angiography showed total occlu-
sion of the ectopic LCx, most likely due to previously unnoticed 
local dissection beyond the distal stent, successfully remedied 
with thromboaspiration (Export® AP catheter; Medtronic, 
Inc., Minneapolis, MN, USA) and implantation of a new stent 
(Endeavor Resolute 2.5/24 mm); the RCA stent was patent. 
186
HOSPITAL CHRONICLES 6(4), 2011
tAbLE 2. Comparative Data in the Three Stent Groups
sEs sEs+other DEs sEs+bMs All Patients P value
Patients 104 122 34 260
Age (years) 62.5±12 64.8±11.8 65.8±10.7 64±11.7 NS
Coronary risk factors
Smoking 48 (46%) 52 (43%) 13 (38%) 113 (43%) NS
Hypercholesterolemia 85 (82%) 104 (85%) 28 (82%) 217 (83%) NS
Hypertension 61 (59%) 79 (65%) 23 (68%) 163 (63%) NS
Diabetes 42 (40%) 44 (36%) 12 (35%) 98 (38%) NS
Lesion characteristics
A 3 (2.9%) 0 (0%) 1 (2.9%) 4 (1.5%) NS
B1 53 (51%)* 40 (32.8%)* 16 (47.1%) 109 (41.9%) 0.011*
B2 29 (27.9%) 42 (34.4%) 9 (26.5%) 80 (30.8%) NS
C 19 (18.3%)* 41 (33.6%)* 8 (23.5%) 68 (26.2%) 0.016*
LVEF 51±12% 45±12% 55±8% 50±11% NS
Vessels stented 1.3±0.5 1.8±0.8 1.6±0.6 1.6±0.7 <0.01
Lesions 2.1±0.9 3.95±1.7 3.1±1.4 3.1±1.6 <0.003
Stents 1.7±0.7 3.4±1.3 2.8±1.0 2.6±1.3 <0.001
Diameter stenosis 88±9% 88±7% 88±6% 88±8% NS
Reference diameter (mm) 2.9±0.3 2.9±0.3 2.9±0.3 2.9±0.31 NS
Pre-intervention MLD 0.57±0.39 0.67±0.3 0.64±0.33 0.63±0.35 NS
Post-intervention MLD 2.9±0.3 2.9±0.3 3.00±0.3 2.9±0.33 NS
Use of IIb/IIIa agents 39 (38%)* 56 (46%) 22 (65%)* 117 (45%) 0.011*
Subacute thrombosis 0 (0%) 0 (0%) 1 (2.9%) 1 (0.4%) NS
Complications 2 (1.9%) 13 (10.6%) 4 (11.8%) 19 (7.3%) 0.008
Clinical restenosis 0 (0%) 2 (1.6%) 2 (5.9%) 4 (1.5%) NS
Very late stent thrombosis 
(possible) ***
0 (0%) 1 (0.8%) 0 (0%) 1 (0.4%) NS
LVEF= left ventricular ejection fraction; MLD= minimal lumen diameter (mm); NS= non-significant
***relates to patient with sudden cardiac death at 32 months post-PCI
M U L t I V E s s E L  A N D  M U L t I L E s I O N  P c I
Multivessel PCI and stenting was performed in 120 (46.3%) 
patients, 87 with two-vessel and 33 with three-vessel disease. 
However, among the 140 patients with single vessel disease, 
only 29 had single-lesions, the majority (89.2%) thus account-
ing for a preponderant multilesion PCI in this cohort. Overall, 
a mean number of 1.6±0.7 vessels and a mean number of 
3.1±1.6 (range, 1-9) lesions were dilated. A mean number of 
2.6±1.3 stents were implanted; a total of 43 (16.5%) patients 
received a single stent, while the majority (83.5%) received 
multiple stents. Group A (patients receiving SES alone) re-
ceived the least number of stents (1.7±0.7) compared to the 
other two groups (Table 2). 
A c U t E  M y O c A r D I A L  I N fA r c t I O N
PCI was performed in 81 patients with acute myocardial 
infarction (MI), 42 with ST-elevation MI (STEMI) and 39 with 
non-ST elevation MI (NSTEMI). Primary PCI was performed 
in 28 patients and late PCI (24 hours to 1 week) in 14 patients 
with acute STEMI of anterior location in 19 and inferopos-
terior in 23 patients. Total occlusion was encountered in 24 
and subtotal in the other patients. The dilated and stented 
vessels were the LAD in 43, the RCA in 16, the LCx in 18, 
SVGs in 3 and the LIMA in 1 patient. One additional patient, 
a 70-year-old lady with history of coronary artery bypass 
grafting (CABG) presented in cardiogenic shock; coronary 
angiography revealed critical left main and left circumflex 
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tAbLE 3. Clinical Outcome of 260 Consecutive Patients 
Receiving SES
Initial success of stenting for all vessels 
attempted
257/260 (98.8%)
Procedural Complications
Local dissections (managed with additional 
stenting)
11 (4.2%)
Vessel branch occlusion 1 (0.4%) 
Bleeding 4 (1.5%)
Groin hematomas 3
Retroperitoneal bleeding 1
Vessel rupture & cardiac tamponade 
(managed with pericardiocentesis and 
grafted stent placement)
1 (0.4%)
Subacute stent thrombosis (at 4 days) 1 (0.4%)
In-hospital deaths (CS) 2 (0.8%)
Long-term follow-up (months) 16.3±14.7 (1-58)
Recurrent angina/ACS/MI 12 (4.9%)
Clinical restenosis 4 (1.6%)
Vessel revascularization (CABG) 2 (0.8%)
Deaths 3 (1.2%)
SCD (at 32 months) * 1
CD (post-CABG) (at 20 months) 1
NCD (colon carcinoma) (at 12 months) 1
CVA 3 (1.2%)
Bleeding 5 (2%)
Intracerebral 1
GI bleeding 1
Gingival bleeding 1
Petechiae 2
Overall stent thrombosis 2 (0.8%)
ACS= acute coronary syndrome; AMI= acute myocardial infarction; 
CABG= coronary artery bypass grafting; CD= cardiac death; CS= 
cardiogenic shock; CVA= cerebrovascular accident; D= diagonal 
(branch); ETT= exercise tolerance test; GI= gastrointestinal; LAD= 
left anterior descending; LCx= left circumflex; LIMA= left internal 
mammary artery; LM= left main; MI= myocardial infarction; NCD= 
non-cardiac death; NSTEMI= non-ST elevation myocardial infarction; 
OM= obtuse marginal (branch); PCI= percutaneous coronary 
intervention; Rad= radial (artery); RCA= right coronary artery; RI= 
ramus intermedius; SCD= sudden cardiac death; SES= sirolimus 
eluting stent(s); STEMI= ST-elevation myocardial infarction; SVG= 
saphenous vein graft
* Possible very late stent thrombosis by definition17 
coronary artery lesions and total occlusion of the LAD with 
patent saphenous vein graft to the LAD which though had a 
subtotal occlusion after the anastomosis. PCI was successful 
in restoring patency both to LM/LCx with implantation of one 
stent and also to the distal LAD with implantation of a second 
stent via the SVG. Unfortunately, however, the patient suc-
cumbed despite successful recanalization 3 days later. 
c H r O N I c  t O t A L  O c c L U s I O N
Chronically totally occluded vessels were present in 10 
(3.8%) patients; all but 4 had suffered a previous MI and sub-
sequent functional testing had confirmed viable myocardium 
supplied by the occluded vessel; one patient had prior PCI and 
instent occlusion. All occluded vessels (LAD, n=5; RCA, n=2; 
LCx, n=3) were successfully crossed and dilated initially with 
conventional balloon angioplasty; stents were implanted in all 
patients. Local dissection and thrombus formation occurred in 
one patient, remedied with thromboaspiration and additional 
stenting. Restenosis was suspected in one patient developing 
angina CCS II symptoms at 6 months and repeat coronary 
angiography was recommended which the patient deferred. 
One patient suffered a non-cardiac death (colon cancer) at 
12 months post-PCI. 
U s E  O f  I I b / I I I A  A G E N t s
A platelet glycoprotein IIb/IIIa inhibitor was used during 
the procedures in 117 (45%) patients, tirofiban in 80 patients 
and eptifibatide in 37 patients. A IIb/IIIa agent was mainly used 
for angiographically demonstrated coronary thrombi, local 
dissections, implantation of multiple (>3) and/or long stents, 
ectatic vessels with sluggish coronary flow, primary angioplasty 
and stenting of acute MI, or high-risk lesions in diabetic pa-
tients or lesions in venous grafts. Complications related to use 
of a IIb/IIIa agent included mostly local inguinal and gingival 
bleeding, but there were no cases of thrombocytopenia noted. 
c O M P L I c A t I O N s
During PCI local dissections occurred in 11 (4.2%) patients 
and were managed with additional stent implantation; in one 
patient there was also local thrombosis noted in a dissected 
right coronary artery (RCA) which was recanalized from 
chronic total occlusion and thromboaspiration was successfully 
employed. Branch (PDA) occlusion occurred in one patient 
undergoing PCI and stenting of the distal RCA, resulting in 
small CK rise. Non-q wave myocardial infarction, as based 
on CK elevation, was noted in one additional patient. Vessel 
rupture leading to cardiac tamponade occurred in one patient 
having PCI performed in two vein grafts; a calcified diagonal 
branch ruptured during stenting just beyond the distal anasto-
mosis of the graft. The patient was managed successfully with 
prompt pericardiocentesis and grafted stent placement; at 
the latest follow-up at 33 months he has been doing very well 
remaining free of angina symptoms. Subacute stent thrombosis 
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occurred in one patient at 4 days, as discussed above, and was 
successfully managed with stent implantation (Fig. 1). Bleed-
ing complications were observed in 4 patients receiving IIb/
IIIa inhibitors, 3 groin hematomas and one retroperitoneal 
bleeding, the latter requiring blood transfusion. The no-reflow 
phenomenon occurred in two patients, significantly improved 
after intracoronary use of nitroglycerin and verapamil and 
intravenous administration of a IIb/IIIa agent; thromboaspira-
tion of heavy thrombotic load was required in one additional 
patient for flow restoration. 
Two in-hospital deaths occurred. One patient with prior 
CABG presenting with cardiogenic shock had a successful 
fIGUrE 1. A 61-year-old patient who suffered an acute non-ST elevation infero-lateral myocardial infarction underwent coronary 
angiography, which revealed subtotal proximal occlusion of both the RCA (also followed by local aneurysmal dilatation) and an 
ectopic circumflex coronary artery (also having a distal critical stenosis) (panel A). Adhoc PCI and stenting were successfully per-
formed with use of a grafted stent for the RCA and 3 Cypher stents for the circumflex to cover both the proximal and distal lesions 
(panel B). Despite having received loading doses of aspirin and clopidogrel and infusion of tirofiban, 4 days later the patient devel-
oped subacute stent thrombosis of the ectopic circumflex coronary artery (arrow, panel C), which was restored with thromboaspi-
ration (panel D) and implantation of an additional stent at the distal lesion, just at the end of the previous stent (arrow, panel D). 
RCA= right coronary artery; PCI= percutaneous coronary intervention 
PCI of the native left main and circumflex coronary artery 
and the left anterior descending via a venous graft but finally 
succumbed 3 days later. Another patient presenting with lateral 
NSTEMI, initially successfully revascularized via a 2-vessel 
(circumflex and RCA) PCI procedure, developed heart failure 
and cardiogenic shock to which he succumbed 5 days later. 
Thrombocytopenia was not observed after administration of a 
IIb/IIIa agent in any patient. No patient in this series required 
emergency CABG. 
L O N G -t E r M  f O L L O w - U P
During long-term clinical follow-up, available in 244 
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(94.6%) patients, over 16.3±14.7 months, 12 (4.9%) patients 
had recurrent angina (Fig. 2) or acute coronary syndrome or 
MI, but restenosis was documented angiographically in only 
4 (1.6%) patients, of whom 2 underwent CABG at 2 and 8 
months after PCI respectively, while the other 2 were man-
aged medically. One additional patient died suddenly at 32 
months after PCI, by definition a suspect for “possible” very 
late stent thrombosis; this was an elderly gentlemen, aged 80 
years, with prior CABG, who presented initially with inferior 
MI and underwent PCI and stenting of a subtotal occlusion of 
a saphenous vein graft to the RCA. There were two additional 
deaths, one cardiac (of pump failure one year after CABG) 
and one non-cardiac (of metastatic colon cancer) at 20 months 
and 12 months post-PCI respectively. Three (1.2%) additional 
patients suffered a stroke during follow-up. Bleeding occurred 
in 5 (2.1%) patients, including 1 intracerebral hemorrhage, 1 
gastro-intenstinal bleeding, 1 gingival bleeding and 2 pete-
chiae. Survival curve analysis with the Kaplan Meier method 
revealed excellent survival free of events (death, MI, stroke, 
repeat revascularization or restenosis) in all three groups (Fig. 
3). Survival free from events was 98%, 96%, and 97% at 12 
months and 95%, 90% and 97% at 24 months for groups A, 
B and C respectively; long-rank (Mantel-Cox) p value= 0.27.
D I s c U s s I O N
“ r E A L  w O r L D ”  s I N G L E  O P E r A t O r 
E x P E r I E N c E  w I t H  t H E  c y P H E r  s t E N t
In this prospective series of 260 patients receiving a SES 
with or without additional DES and/or BMS, the Cypher 
stent but also the other stents implanted (with the Endeavor 
Resolute and Genous stents as the predominant other non-
SES stents) performed very well acutely and long-term over a 
mean follow-up of approximately 16 months. This was mainly 
a series of patients having an adhoc PCI (93.8%) during the 
same session as coronary angiography, with a preponderance 
of acute coronary syndromes (79.2%). The majority (89.2%) 
had multilesion PCI with 46.3% having two- or three-vessel 
disease with type B/C lesions in 98.5%. Of the 140 patients 
fIGUrE 2. A 62-year gentleman with symptomatic ischemia (group A) in the territory of the LAD underwent PCI of a subtotal 
occlusion of the LAD (panel A) with implantation of a single Cypher stent (panel C). His RCA had no disease. Three years later 
the patient developed CCS class III angina symptoms leading to repeat coronary angiography which demonstrated patency of the 
LAD stent (panel D) and a new lesion of the PDA branch of the RCA (panel E). He received a new Cypher stent (panel F) and he 
has since been doing very well remaining asymptomatic at 18 months later. CCS= Canadian Cardiovascular Society (classification); 
LAD= left anterior descending coronary artery; PCI= percutaneous coronary intervention; PDA= posterior descending coronary 
artery; RCA= right coronary artery
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having single-vessel disease, only 29 had single lesions. 
The PCI procedure was completely successful in revascu-
larizing and stenting all vessels attempted in 257 (98.8%) of 260 
patients; in 3 patients the procedure was partially successful 
with failure occurring in revascularizing one of two (n=2) or 
one of three (n=1) vessels attempted. Procedural complica-
tions comprised mainly local dissections in 11 (4.2%) patients, 
all managed successfully with additional stenting, one vessel 
rupture leading to cardiac tamponade promptly managed with 
pericardiocentesis and grafted stent implantation, and local 
bleeding in 4 patients managed conservatively. Subacute stent 
thrombosis developed in one (0.4%) patient and was also 
managed successfully at a repeat procedure. 
The long-term course of this cohort was excellent with re-
current symptoms reported in 12 (4.9%) patients but restenosis 
was documented in 4 (1.6%). There occurred 3 deaths, one 
sudden, one cardiac and one non-cardiac, and 3 strokes during 
follow-up. While all patients were maintained on long-term 
dual antithrombotic therapy for at least 2 years, only 5 patients 
developed late hemorrhagic complications which were serious 
in 2 patients having cerebral and gastrointestinal bleeding, 
respectively. Long-term survival free of cardiovascular events 
(death, MI, stroke, repeat revascularization or restenosis) was 
excellent in all three groups: 98%, 96%, and 97% at 12 months 
and 95%, 90% and 97% at 24 months for groups A, B and C 
respectively (Fig. 2). The “dreaded” complication of late stent 
thrombosis could be suspected as possible in one (0.4%) pa-
tient who sustained sudden cardiac death at 32 months after the 
initial PCI procedure. Thus, the overall rate of stent thrombosis 
in this series was limited to 2 patients (0.8%).
c O r O N A r y  s t E N t I N G  t E c H N I q U E
The present study demonstrates in a series of 260 receiving 
a SES among 675 consecutive patients of a single-operator ex-
perience that SES implantation alone or combined with other 
DES and/or BMS by applying a uniform and consistent ap-
proach of oversizing and high-pressure deployment inflation, 
resulted in high procedural success, very low subacute stent 
thrombosis and very low clinical restenosis rates. Combined 
with long-term use of antiplatelet agents the late stent throm-
bosis phenomenon was almost eliminated; only one case of a 
patient with sudden death at 32 months meets the definition 
for “possible” very late stent thrombosis. Although these are 
results from a nonrandomized series of patients, they involve 
unselected patients and lesion types, with complex multile-
sion and multivessel PCI and thus reflect more accurately 
“real-world” practice in a large tertiary center, rather than 
randomized studies, with their selection bias and stringent 
selective criteria applied. These results are much better, albeit 
in a smaller cohort, than those recently reported in an observa-
tional retrospective study of a large patient population receiv-
ing different types of DES, whereby the incidence of late stent 
thrombosis ranged from 0.83% to 1.7% at two- and three-year 
follow-up.18 They are also better than those of the SYNTAX 
trial which showed a 3.3% incidence of stent thrombosis at 1 
year,19 and of the ARTS II trial indicating a 3.8% incidence 
of stent thrombosis at 3 years.20 Our patient population un-
derwent complex multilesion and multivessel procedures with 
fIGUrE 3. Kaplan-Meier analysis of cumulative survival of the three groups free from events (death, myocardial infarction, stroke, 
restenosis, repeat revascularization); survival free from events was 98%, 96%, and 97% at 12 months and 95%, 90% and 97% at 24 
months for groups A, B and C respectively; long-rank (Mantel-Cox) p value= 0.27.
Number at risk 
Group A 104 55 34 27
Group B 122 57 24 8
Group C  34 29 25 14
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implantation of multiple and long stents, features which appar-
ently confer higher rates of stent thrombosis.19,21,22 However, 
this was obviated and the difference noted, we believe, relates 
first to the technique adopted routinely in our study with stent 
oversizing and high-pressure stent deployment and second 
to the longer duration of antiplatelet therapy in our patients 
(>24 months vs >6-12 months).
Most importantly, compared to other studies, the present 
study reports on a more clinically relevant endpoint, which 
is the clinical, rather than the angiographic, restenosis rate. 
During long-term follow-up a patient-oriented cardiovascular 
end-point was utilized for evaluation, which included all death, 
MI, stroke, repeat revascularization and clinical restenosis, 
mostly following the consensus criteria of the Academic Re-
search Consortium for DES study end-points.17
A small (13.1%) non-DES stent use rate in this series 
reflects an evolution over time with the exponential growth of 
DES use, due mainly to a significant reduction of the restenosis 
rates.3 However, a major drawback of DES, the occurrence 
of late stent thrombosis, was highlighted a few years ago and 
threatened to limit the use DES in favor of BMS.3-7 Never-
theless, the data accumulated todate offered some increased 
re-assurance with regards to the risks of this “dreaded” com-
plication. Since then newer generation stent devices appeared 
and are being designed, promising to overcome the limitations 
of the first generation stents by providing improved flexibility 
and deliverability, better expansion, smoother angiographic 
appearance and possibly less thrombogenicity mainly by novel 
coatings or by being biodegradable, all leading to quicker, 
more simplified and, most importantly, safer procedures. 3,23 
The technique of stent oversizing and high-pressure deploy-
ment adopted in this series, combined with prolonged dual 
antiplatelet agent use, has apparently contributed significantly 
to the very favorable acute and long-term results in this unse-
lected patient cohort.
M U L t I V E s s E L  A N D  M U L t I L E s I O N  P c I
The majority (89.2%) of patients in these series had mul-
tilesion PCI. A total of 46.3% had multivessel (two- or three-
vessel) PCI. Even among the 140 patients having single-vessel 
disease, 111 patients had multiple lesions dilated and stented. 
The great majority (98.5%) of all lesions were complex type 
B/C lesions. Overall, a mean number of 1.6±0.7 vessels and 
a mean number of 3.1±1.6 (range, 1-9) lesions were dilated. 
The use of DES vs BMS in multilesion and multivessel PCI is 
favored in non-dedicated trials and registries with regards to 
repeat revascularization and major cardiac events, but rand-
omized trials are lacking. 3 Importantly, comparing PCI using 
DES with CABG, the results from trials, including SYNTAX, 
favor CABG; clinical outcomes between PCI and CABG are 
only comparable among patients in the lowest SYNTAX score 
tercile,3 although in the 5-year follow-up data from the ARTS 
II trial, safety of SES was comparable to CABG and superior 
to BMS, and the cardiac event rate was lower with BMS, but 
higher with CABG.18,24 Nevertheless, one third of the events 
encountered in the SES group could have been prevented if 
stent thrombosis had been lower.24 These not-withstanding, it 
appears that in patients with discrete and non-diffuse lesions 
and of course in those who refuse surgery or have high and 
prohibitive surgical risk scores, PCI with DES appears an 
important option.
A c U t E  A N D  c H r O N I c  t O t A L  O c c L U s I O N
PCI and stenting was successfully performed in 81 patients 
with acute MI, as primary (n=28) and late (n=14) PCI in 42 
STEMI, and in 39 NSTEMI. Total culprit vessel occlusion was 
encountered in 24 and subtotal in the other patients. Despite 
initially successful revascularization, two in-hospital deaths 
occurred in patients presenting in cardiogenic shock and heart 
failure. During follow-up, MI recurred in 3 patients of whom 
one was submitted to CABG, one to non-target vessel PCI and 
the other treated medically; anginal symptoms developed in 
another 2 patients who deferred repeat coronary angiography; 
one patient died suddenly at 32 months. Studies examining 
the use of DES in patients with acute MI have indicated no 
significant difference between BMS and DES in terms of mor-
tality and stent thrombosis, with DES leading to a significant 
reduction in repeat target lesion or vessel revascularization.3,25 
A recent study evaluated the 3-year long-term safety of SES 
in 2308 patients with acute coronary syndrome and found 
that these patients had a greater risk of early (first one year) 
adverse events (death, MI, stent thrombosis), but the risk of 
late (beyond the first year) events was similar to those without 
acute coronary syndrome.26
Chronic total occlusions were successfully treated in 10 
patients (3.8%) in this series. All occluded vessels (100%) were 
successfully crossed and dilated initially with conventional bal-
loon angioplasty; stents were implanted in all patients. Reste-
nosis was only suspected in one patient who developed CCS 
class II symptoms at 6 months but deferred repeat coronary 
angiography. Stenting of chronically totally occluded vessels 
with DES as compared with BMS has been shown to be equally 
efficacious and safe in comparative trials, which though have 
demonstrated significantly reduced angiographic and clinical 
restenosis rates and target lesion or vessel revascularization 
with DES.23,27
A N t I t H r O M b O t I c  A N D  s t A t I N  t H E r A P y
All patients were receiving aspirin before and indefinitely 
after the revascularization procedures. All patients continued 
receiving additionally clopidogrel (75 mg daily) for at least 24 
months after the procedure. An attempt was made for elec-
tive procedures to have the patient receive pretreatment with 
both aspirin and clopidogrel for 3 days before the scheduled 
procedure. This type of pretreatment strategy (>3 days) has 
been endorsed by several studies indicating a lower risk of 
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procedural non-Q-wave MI, in addition to the protection 
offered from subacute stent thrombosis.28,29 However, the 
majority (79%) of patients in this series were patients with 
acute coronary syndromes admitted via the emergency room or 
transferred from other institutions and they all received load-
ing doses of both antiplatelet agents at least upon their arrival 
in the emergency room. They also received a statin regardless 
of their cholesterol status and this may have contributed to the 
favorable outcome as suggested by recent data.30,31 All these 
measures probably complemented a uniform and consistent 
approach of stent oversizing and high-pressure inflation, a 
strategy that can apparently optimize the clinical outcome of 
coronary stenting.12 
In patients (n=117) with intracoronary thrombi, or dis-
sections or angiographically high-risk lesions, particularly in 
diabetic patients, eptifibatide or tirofiban was administered 
with very favorable outcome. Most likely, early sheath re-
moval with use of a closure device contributed to minimize 
bleeding complications particularly in this patient subgroup. 
Importantly, there were no events of thrombocytopenia noted 
in these patients. Cost constraints and concerns about the 
bleeding risk have by and large reduced the use of IIb/IIIa 
agents during PCI over the recent years, having also been 
supplanted by dual antiplatelet therapy given as pre-treatment 
or in a periprocedural loading scheme.29 
With regards to the duration of dual antiplatelet therapy 
after DES implantation, due to the “dreaded” risk of late stent 
thrombosis, guidelines from cardiological societies have been 
updated more than once recently and the latest ones recom-
mend at least one-year duration for this therapy.8,9 Long before 
these clinical guidelines were issued, we have been advising 
our patients to continue receiving dual antiplatelet therapy 
for at least two years. This recommendation has most likely 
contributed to almost elimination of late stent thrombosis in 
our patient cohort, albeit without having all the data regarding 
patient compliance with dual antiplatelet therapy. “Possible” 
very late stent thrombosis may be suspected in only one pa-
tient who sustained sudden death at 32 months after the PCI 
procedure. Of course, there is concern of late bleeding prob-
lems and problems of patient handling when need for other 
surgical procedures emerges, but late bleeding occurred in a 
small number of our patients (Table 3), among whom only two 
(0.8%) had severe bleeding events and these were patients 
requiring triple antithrombotic therapy. However, studies have 
shown that even during the first year, life-threatening bleeding 
complications are not the main reasons for discontinuing dual 
antiplatelet therapy and this needs to be addressed in order to 
avoid unjustified discontinuation of what appears nowadays 
to be life-saving therapy for patients receiving DES.32 Finally, 
with the new antiplatelet agents (prasugrel and ticagrelor) 
currently becoming available, the scenery of stent thrombosis 
in the future may not be the same.
s t U D y  L I M I t A t I O N s
The study is limited by the lack of randomization. However, 
it reflects clinical practice in a uniform approach by a single 
operator. The results reported apply to the technique and 
type of stents (mainly the Cypher, Endeavor, Genous, Xience, 
NirFlex, Costar, MGuard, and Jostent stents) used in the study. 
Another limitation is the lack of routine angiographic follow-
up, relying mainly on clinical grounds and exercise testing or 
radionuclide scintigraphy for initial detection of restenosis, 
subsequently confirmed by angiography. However, this ap-
proach avoids any unnecessary revascularization procedures 
usually triggered by the “occulostenotic reflex”.33 Also, the 
lack of intravascular ultrasound use in this series may be 
considered a limitation by some, but this was circumvented by 
oversizing and high-pressure stent deployment. Furthermore, 
current stent delivery systems utilize high-pressure balloons, 
which obviate the need for post-deployment extra dilatation. 
Overall, this proposed approach to coronary stenting appears 
more practical and cost-effective strategy by avoiding delay 
and costs incurred by use of ultrasound and extra balloons 
for additional high-pressure inflation. Finally, these results 
pertain to patients with a mean left ventricular ejection of 
50% and may not relate to patients with more compromised 
left ventricular function. 
c L I N I c A L  I M P L I c A t I O N s
The results of the present study indicate in a single-opera-
tor experience of 260 patients receiving SES alone or combined 
with other DES and/or BMS among 675 consecutive patients 
undergoing PCI that the technique of stent oversizing and high-
pressure deployment with adjunctive therapy with aspirin and 
clopidogrel led to high procedural success (99%), very low rate 
of subacute (0.4%) or late stent thrombosis (0.4%), and a very 
low clinical restenosis rate (<6%). Pretreatment for at least 
3 days before an elective procedure with the antithrombotic 
regimen of combined aspirin and clopidogrel or aspirin and 
clopidogrel loading for urgent PCI with selective periproce-
dural use of a IIb/IIIa agent may be an important adjunctive 
measure to reduce the acute complication rate during PCI 
and stenting. Long-term use of combined antiplatelet therapy 
with aspirin and clopidogrel drastically reduced the risk of late 
stent thrombosis without increasing the risk of serious late 
bleeding complications. 
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